1,886,715 Shares in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Purchased by Towercrest Capital Management

Towercrest Capital Management acquired a new stake in shares of Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,886,715 shares of the company’s stock, valued at approximately $299,000.

Separately, Private Advisor Group LLC boosted its stake in Matinas BioPharma by 31.1% during the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock valued at $73,000 after acquiring an additional 80,000 shares during the last quarter. 11.77% of the stock is owned by institutional investors.

Matinas BioPharma Price Performance

MTNB stock traded down $0.19 during mid-day trading on Friday, hitting $3.45. 93,224 shares of the company were exchanged, compared to its average volume of 28,284. The firm has a market cap of $865.33 million, a P/E ratio of -28.75 and a beta of 1.70. Matinas BioPharma Holdings, Inc. has a twelve month low of $3.28 and a twelve month high of $44.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

Matinas BioPharma Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.